Ionetix Corporation announced FDA approval of its Abbreviated New Drug Application for Gallium Ga-68 gozetotide, a radioactive diagnostic agent for PSMA-PET imaging in prostate cancer patients. The approval expands the company's portfolio of positron emission tomography diagnostics and enables distribution through its multi-site network of PET facilities.